Cosentyx (secukinumab) - Articles and news items

Novartis plans head-to-head studies of Cosentyx versus Humira

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis…

Cosentyx superior to Stelara in achieving sustained skin clearance in psoriasis

Industry news / 7 March 2016 / Victoria White

In the CLEAR study, Cosentyx (secukinumab) was significantly better than Stelara (ustekinumab) in achieving PASI 100 (clear skin) response at 52 weeks…

Cosentyx to achieve blockbuster status

Industry news / 27 January 2016 / Victoria White

Alexandra Annis states that Cosentyx’s latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies…

FDA approves Novartis’ Cosentyx for AS and PsA

Industry news / 18 January 2016 / Victoria White

Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)…

CHMP recommends approval of Cosentyx for ankylosing spondylitis and psoriatic arthritis

Industry news / 23 October 2015 / Victoria White

Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis…

Secukinumab demonstrates efficacy in psoriatic arthritis

Industry news / 1 October 2015 / Victoria White

Secukinumab is the first interleukin-17A inhibitor to demonstrate efficacy in a Phase III study in patients with active psoriatic arthritis…

New results show sustained efficacy with secukinumab over one year in psoriatic arthritis patients

Industry news / 29 June 2015 / Victoria White

New one year results from the pivotal Phase III FUTURE 2 study of Novartis’ secukinumab in psoriatic arthritis (PsA) have been published.


Novartis to present new late-breaking Cosentyx data at AAD 2015 showing significant patient benefit in achieving clear skin

Industry news / 13 March 2015 / Novartis

Novartis announced that new results for Cosentyx(TM) (secukinumab) in moderate-to-severe plaque psoriasis, including detailed findings from the head-to-head CLEAR study and long-term data from the Phase III program, will be presented as late breaking research at the 73rd Annual Meeting of American Academy of Dermatology…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...